ReviewAmerican journal of clinical dermatology2021
Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges.
Review in American journal of clinical dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A genome-wide cross-trait analysis identifies shared loci and causal relationships of obesity and lipidemic traits with psoriasis.Frontiers in immunology · 2024Pooled it
- Joint Relationship of Cardiovascular-kidney-metabolic Syndrome and Psoriasis with All-cause and Cause-specific Mortality in Adults: A Population-based Analysis.Acta dermato-venereologica · 2026Article
- Mechanistic insights into psoriasis and type 2 diabetes mellitus comorbidity - Implications for treatment: A review.Biomolecules & biomedicine · 2026Review
- The impact of body mass index on the relationship between psoriasis and Osteopenia: a mediating analysis based on NHANES (2003-2006).Archives of dermatological research · 2025Article
- Computational identification of perturbed pathways in type 2 diabetes mellitus patients reveals necroptosis and NF-κB pathways with potential for susceptibility to psoriasis.Journal of biosciences · 2025Article
- Skin Microbiome in Health and Disease: Mechanisms and Emerging Therapeutic Strategies.Clinical, cosmetic and investigational dermatology · 2025Review
- Restless Legs Syndrome in Psoriasis: A Multicenter Study on Its Prevalence, Severity, and Impact on Patients.Clinical, cosmetic and investigational dermatology · 2025Article
- Residual metabolic burden in young psoriasis patients successfully treated with biologics.Archives of dermatological research · 2024Article
- Managing the Patient with Psoriasis and Metabolic Comorbidities.American journal of clinical dermatology · 2024Review
- Synergistic impact of psoriasis and hypertension on all-cause mortality risk: A prospective cohort study.PloS one · 2024Article
- Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes.Frontiers in microbiology · 2023Article
- Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time.International journal of molecular sciences · 2022Review
- Activation of the STING-IRF3 pathway involved in psoriasis with diabetes mellitus.Journal of cellular and molecular medicine · 2022Article
- Metabolic Syndrome in Psoriasis Patients-an Observational Study.Current health sciences journalArticle
- Interaction Effect of Psoriasis and Cancer on the Risk of All-Cause Mortality: A Prospective Cohort Study of NHANES Data.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory disease that affects 2-3% of the population worldwide. It is associated with plaques, psoriatic arthritis, and metabolic syndrome and its components, including obesity, diabetes, dyslipidemia, nonalcoholic fatty liver disease, and cardiovascular disease. In this review, we highlight the shared pathogenic pathways leading to the comorbid existence of both diseases and the impact of drugs used for psoriasis on metabolic syndrome and vice versa. Persistent inflammation is common to both diseases. They share increased inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin-6. Biologics have revolutionized the treatment of plaque psoriasis and also have a positive impact on metabolic syndrome. There is some evidence that TNFα inhibitors decrease insulin resistance and improve glycemic indices. Some psoriasis treatments may result in decreased body weight. Lifestyle measures used in the management of metabolic syndrome, such as weight loss, exercise, and healthy diet, are beneficial in patients with psoriasis. Considering the association between metabolic syndrome and psoriasis, we recommend screening patients with psoriasis for metabolic syndrome with clinical examinations and laboratory tests. Patients with a co-diagnosis of these diseases deserve special attention for optimal treatment.
Indexed as
Identifiers
33586126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.